600774.SH
汉商集团
SSE · Healthcare · Medical - Pharmaceuticals · CN
CNY 7.17
−2.05%Year over year
Reported trailing growth
- Revenue
- -8.6%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- -3.5%
- Operating cash flow
- +0.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -9.4%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- +94.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026